文献速递新发突发、热带与寄生虫病

血红蛋白病患者的青蒿素类抗疟治疗:一项系统综述

Artemisinin Therapy for Malaria in Hemoglobinopathies: A Systematic Review.
PubMed 文献 · Clin Infect Dis · 2018-01-01

本文系统综述了α-地中海贫血、镰状细胞病、β-地中海贫血和血红蛋白E对青蒿素类药物处置及抗疟活性的影响。现有证据未显示血红蛋白病会明显改变青蒿素类药物的体内处置;尽管体外研究提示地中海贫血红细胞内培养的恶性疟原虫对青蒿素衍生物相对耐药,但其平均50%抑制浓度远低于推荐治疗剂量后的体内血浆浓度。目前无临床研究表明血红蛋白病会显著降低青蒿素联合疗法(ACT)对无并发症疟疾的疗效,因此推荐剂量的ACT在该患者群体中仍然适用。

要点

  • 无令人信服的证据表明血红蛋白病会影响青蒿素类药物的体内处置。
  • 地中海贫血红细胞中恶性疟原虫的体外IC50虽相对较高,但仍远低于推荐剂量后的体内血浆浓度。
  • 无临床研究表明血红蛋白病会显著降低ACT对无并发症疟疾的疗效,推荐剂量仍然适用。

核心结论

  • 无临床研究表明血红蛋白病会显著降低ACT对无并发症疟疾的疗效,推荐剂量的ACT在该患者群体中仍然适用。

研究设计与样本

  • 系统综述,评估α-地中海贫血、镰状细胞病、β-地中海贫血和血红蛋白E中青蒿素类药物处置及抗疟活性的相关数据。

主要发现

  • 无令人信服的证据表明血红蛋白病会影响青蒿素类药物的体内处置。
  • 体外研究显示地中海贫血红细胞中培养的恶性疟原虫对青蒿素衍生物相对耐药,但平均50%抑制浓度(IC50)远低于推荐治疗剂量后的体内血浆浓度。
  • 使用镰状细胞病红细胞培养的恶性疟原虫IC50未见升高,镰状细胞病患者治疗后寄生虫清除延迟可能反映脾功能减退。

临床怎么用

  • 无临床研究表明血红蛋白病会显著降低ACT对无并发症疟疾的疗效,推荐剂量的ACT在该患者群体中仍然适用。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Artemisinin derivatives are widely used antimalarial drugs. There is some evidence from in vitro, animal and clinical studies that hemoglobinopathies may alter their disposition and antimalarial activity. This review assesses relevant data in α-thalassemia, sickle cell disease (SCD), β-thalassemia and hemoglobin E. There is no convincing evidence that the disposition of artemisinin drugs is affected by hemoglobinopathies. Although in vitro studies indicate that Plasmodium falciparum cultured in thalassemic erythrocytes is relatively resistant to the artemisinin derivatives, mean 50% inhibitory concentrations (IC50s) are much lower than in vivo plasma concentrations after recommended treatment doses. Since IC50s are not increased in P. falciparum cultures using SCD erythrocytes, delayed post-treatment parasite clearance in SCD may reflect hyposplenism. As there have been no clinical studies suggesting that hemoglobinopathies significantly attenuate the efficacy of artemisinin combination therapy (ACT) in uncomplicated malaria, recommended artemisinin doses as part of ACT remain appropriate in this patient group.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Sugiarto SR, Moore BR, Makani J, et al. Artemisinin Therapy for Malaria in Hemoglobinopathies: A Systematic Review. Clin Infect Dis. 2018. PMID: 29370347. doi:10.1093/cid/cix785

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。